DE-BIOCORP
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the design, development and manufacture of innovative medical devices, today announced an alliance with Belgium-based AARDEX Group, the world leader in medication adherence solutions.
This alliance is to combine BIOCORP’s connected add-on solutions for drug delivery devices with AARDEX’s proprietary Medication Event Monitoring System (MEMS®) and offer a comprehensive solution to patients and healthcare providers to effectively measure and manage medication adherence. The financial terms of the agreement have not been disclosed, however the first initiative will be to integrate BIOCORP’s Injay connected solution for Pre-filled syringes (PFS) to AARDEX’s MEMS Adherence Software (MEMS AS® ), to target medicines delivered by PFS with potential applications in the field of Rheumatoid Arthritis, Multiple Sclerosis, Ophthalmology, Psoriasis or Cardiovascular diseases. The roadmap also includes integration with BIOCORP’s other connected devices, to cover further chronic conditions in the field of injectable, respiratory, and beyond.
David Dalla Vecchia, CEO and Financial Lead of AARDEX Group, said: "We are delighted to announce our partnership with BIOCORP. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment. Partnering with BIOCORP - a true pioneer in connected devices - will significantly contribute to that objective and bring together a wealth of knowledge and experience to help meet the needs of today’s clinical trials, patients and healthcare providers.”
Éric Dessertenne, CEO of BIOCORP, concluded: “This collaboration with AARDEX Group brings a strong added value to our products and to our targeted users. Thanks to the integration with MEMS AS, a unique solution that analyzes deeply patient patterns and behaviors, we will go beyond just monitoring treatment adherence, by providing comprehensive and tailored solutions to boost patient’s engagement and effectively manage this issue. AARDEX specific expertise in clinical trials is also a strong asset and will enable us to create relationships with pharma companies right from the development stage of a drug”.
Medication adherence issues are well known by all healthcare stakeholders and its clinical and commercial impact have been quantified and heavily documented for many years now. The World Health Organization has stated that, in developed countries, adherence to long-term therapies in the general population is only around 50%. But this issue is not limited to commercialized drugs and real-life conditions, it also massively affects clinical trials, which impacts assessment of drug efficacy.
ABOUT AARDEX GROUP
AARDEX Group is the world leader in digital solutions to measure and manage medication adherence. Located in Belgium, in Switzerland and in the U.S., AARDEX develops and markets digital solutions for adherence-enhancing strategies in clinical trials, research settings, and professional healthcare systems. AARDEX is the central actor of a complete ecosystem that combines its MEMS® Adherence Software with a wide range of smart packages and devices that measure patient adherence across all routes of drug administration. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment.
For more information, visit www.aardexgroup.com
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005883/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International Expands its Partnership with Scuderia Ferrari HP, Launching a Bold New Chapter in Their Long-Standing Relationship3.12.2025 12:00:00 CET | Press release
ZYN Branding to be present in selected races, starting with the Formula 1 Etihad Airways Abu Dhabi Grand Prix 2025 Philip Morris International Inc. (NYSE: PM) today announced an expanded partnership with Scuderia Ferrari HP and with Ferrari Challenge Trofeo Pirelli—the single-marque motorsport championship created in 1993—for the 2026 season and beyond. This next chapter introduces one major development: the ZYN brand of nicotine pouches—the number one nicotine pouch brand globally1—will feature on Scuderia Ferrari HP Formula 1 liveries at select races throughout the seasons. This bold new chapter reinforces a spirit of relentless innovation and unforgettable experiences that has defined the partnership for more than five decades—making it one of the strongest in sports history. To mark this moment, ZYN branding will first feature on the Scuderia Ferrari HP car livery during the Abu Dhabi Grand Prix 2025 scheduled for December 7. “PMI shares with Scuderia Ferrari HP the pursuit to inno
LumRisk Announces Strategic Reset and USD 5 Million Capital Commitment to Accelerate Its Transformation Toward an AI-Driven QIS and Multi-Asset Platform3.12.2025 11:30:00 CET | Press release
LumRisk today announced a major milestone in its evolution, with the approval and implementation of a comprehensive corporate reset. This includes the restructuring of legacy obligations and the reinforcement of the company’s balance sheet. These measures establish a strong foundation for a new phase of accelerated global growth across LumRisk’s core domains: Quantitative Investment Strategies (QIS) and Multi-Asset Analytics. As part of this strategic renewal, LumRisk has secured shareholder approval for a USD 5 million equity commitment, subject to customary conditions. This capital is intended to be deployed to scale the company’s next-generation platform, reinforce its data and technology capabilities, and deepen its offering across the global QIS ecosystem. In parallel, LumRisk is implementing a new management-led corporate structure, under which the leadership team will assume full operational control and a majority equity position upon finalisation of the process. This realignmen
Reply Awarded a 2025 AWS Partner of the Year Award3.12.2025 10:00:00 CET | Press release
Reply recognized as winner for EMEA Partner of the Year, Industry Energy & Utilities, one of many AWS Partners around the globe that help their customers drive innovation Reply [EXM, STAR: REY] is pleased to announce it is a recipient of a 2025 Geography and Global AWS Partner Award, recognizing leaders around the globe that are playing key roles in helping their customers drive innovation and build solutions on Amazon Web Services (AWS). Reply has been named the winner of the EMEA Partner of the Year – Industry Energy & Utilities award, which recognizes top AWS Partners with the AWS Energy Competency, which help customers build and implement advanced solutions powered by AWS across the industry value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251203089630/en/ Through its specialized companies — including Airwalk Reply, Comsysto Reply, Data Reply, Sense Reply, and Storm Reply — Reply leverages AWS capabilities to
FiRa Consortium Unveils FiRa Core 4.0 Specifications and Certification Program3.12.2025 10:00:00 CET | Press release
Featuring UL-TDoA, Aliro UWB updates, and expanded certification The FiRa® Consortium announces the release of its Core 4.0 Specifications and Certification Program, notable milestones in ultra-wideband (UWB) technology development. These updates complete the work of IEEE 802.15.4-2024 features to fulfill FiRa-defined use cases. They also enhance FiRa’s capabilities, enabling seamless interoperability and unlocking new possibilities for precise and secure ranging and positioning in diverse applications. Features of the FiRa Core 4.0 Specifications and Certification Program The FiRa Core 4.0 Specifications include updates that support expanded functionality and continued ecosystem growth. UL-TDoA – This feature enables the tracking of assets (UL-TDoA tags) by an infrastructure made of UL-TDoA anchors. The design ensures interoperability between the tags and the infrastructure, which optimizes tag simplicity and power consumption. The flexible design allows easy and customized deployment
Infobip Reports Record Black Friday Interactions as Retailers Accelerate Shift to Richer Customer Experiences3.12.2025 10:00:00 CET | Press release
Black Friday interactions grow by 15% year-on-year, marking a new milestone for Infobip’s global communications platform Infobip, the leading global cloud communications platform for customer engagement, identified a remarkable upswing in its Black Friday messaging traffic, with use of Rich Communication Services (RCS) surging 277% on Black Friday 2025 compared to the previous year. Email also remained a strong channel of choice among both retailers and consumers, showing an impressive 241% year-on-year increase, signaling that promotional and transactional communications continue to drive engagement during shopping peaks. Black Friday is no longer just a single day. The search for attractive deals extends beyond Friday, with consumers from around the globe seeking products, better price offers, and reliable, easy communication channels to connect with their favourite brands. Infobip identified significant increases in interactions not only in North America, but also in other key regio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom